Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Carcinoma, Non-Small-Cell Lung 8Esophageal Squamous Cell Carcinoma 7Stomach Neoplasms 4Recurrence 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Lung Neoplasms 3Colorectal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1NSCLC 1Multiple Pulmonary Nodules 1Mid-low Rectal Cancer 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

halofantrine 2Sorafenib 2trifluridine tipiracil drug combination 1trametinib 1toripalimab 1tislelizumab 1sintilimab 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1lenvatinib 1ledipasvir, sofosbuvir drug combination 1gadolinium ethoxybenzyl DTPA 1fisogatinib 1ficlatuzumab 1camrelizumab 1belinostat 1avelumab 1Trabectedin 1Shadowing Technique, Histology 1Ramucirumab 1Patient Navigation 1Oxaliplatin 1Nutritional Status 1Nivolumab 1Nadroparin 1N-monoacetylcystine 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liver Diseases × tislelizumab × Clear all
NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Sun Yat-sen University

Completed
600 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡